Tobias R. Kollmann

Dr. Tobias R. Kollmann


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2015 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MAMarie-Claire Arrieta
Marie-Claire Arrieta
LSLeah T. Stiemsma
Leah T. Stiemsma
PDPedro A. Dimitriu
Pedro A. Dimitriu
LTLisa Thorson
Lisa Thorson
SRShannon Russell
Shannon Russell
BFB. Brett Finlay
B. Brett Finlay
Asthma is the most prevalent pediatric chronic disease and affects more than 300 million people worldwide. Recent evidence in mice has identified a “critical window” early in life where gut microbial changes (dysbiosis) are most influential in experimental asthma. However, current research has yet to establish whether these changes precede or are involved in human asthma. We compared the gut microbiota of 319 subjects enrolled in the Canadian Healthy Infant Longitudinal Development (CHILD) Study, and show that infants at risk of asthma exhibited transient gut microbial dysbiosis during the first 100 days of life. The relative abundance of the bacterial genera Lachnospira, Veillonella, Faecalibacterium, and Rothia was significantly decreased in children at risk of asthma. This reduction in bacterial taxa was accompanied by reduced levels of fecal acetate and dysregulation of enterohepatic metabolites. Inoculation of germ-free mice with these four bacterial taxa ameliorated airway inflammation in their adult progeny, demonstrating a causal role of these bacterial taxa in averting asthma development. These results enhance the potential for future microbe-based diagnostics and therapies, potentially in the form of probiotics, to prevent the development of asthma and other related allergic diseases in children.

1 July 2021 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
MSManish Sadarangani
Manish Sadarangani
AMArnaud Marchant
Arnaud Marchant
TKTobias R. Kollmann
Tobias R. Kollmann

1 November 2012 in Immunity
Verified
Journal Article
Closed access
TKTobias R. Kollmann
Tobias R. Kollmann
OLOfer Levy
Ofer Levy
RMRuth R Montgomery
Ruth R Montgomery
SGStanislas Goriely
Stanislas Goriely

27 August 2008 in Cytometry Part A
Verified
Journal Article
Open access
PDF file
JLJamie A. Lee
Jamie A. Lee
JSJosef Spidlen
Josef Spidlen
KBKeith Boyce
Keith Boyce
JCJennifer Cai
Jennifer Cai
NCNicholas Crosbie
Nicholas Crosbie
RBRyan R. Brinkman
Ryan R. Brinkman
A fundamental tenet of scientific research is that published results are open to independent validation and refutation. Minimum data standards aid data providers, users, and publishers by providing a specification of what is required to unambiguously interpret experimental findings. Here, we present the Minimum Information about a Flow Cytometry Experiment (MIFlowCyt) standard, stating the minimum information required to report flow cytometry (FCM) experiments. We brought together a cross‐disciplinary international collaborative group of bioinformaticians, computational statisticians, software developers, instrument manufacturers, and clinical and basic research scientists to develop the standard. The standard was subsequently vetted by the International Society for Advancement of Cytometry (ISAC) Data Standards Task Force, Standards Committee, membership, and Council. The MIFlowCyt standard includes recommendations about descriptions of the specimens and reagents included in the FCM experiment, the configuration of the instrument used to perform the assays, and the data processing approaches used to interpret the primary output data. MIFlowCyt has been adopted as a standard by ISAC, representing the FCM scientific community including scientists as well as software and hardware manufacturers. Adoptionof MIFlowCyt by the scientific and publishing communities will facilitate third‐party understanding and reuse of FCM data. © 2008 International Society for Advancement of Cytometry

1 March 2017 in Immunity
Verified
Journal Article
Closed access
TKTobias R. Kollmann
Tobias R. Kollmann
BKBeate Kampmann
Beate Kampmann
SMSarkis K. Mazmanian
Sarkis K. Mazmanian
AMArnaud Marchant
Arnaud Marchant
OLOfer Levy
Ofer Levy

1 December 2009 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
TKTobias R. Kollmann
Tobias R. Kollmann
JCJuliet Crabtree
Juliet Crabtree
ARAnnie Rein-Weston
Annie Rein-Weston
DBDarren Blimkie
Darren Blimkie
FTFrancis Thommai
Francis Thommai
CWChristopher B. Wilson
Christopher B. Wilson
The human neonate and infant are unduly susceptible to infection with a wide variety of microbes. This susceptibility is thought to reflect differences from adults in innate and adaptive immunity, but the nature of these differences is incompletely characterized. The innate immune response directs the subsequent adaptive immune response after integrating information from TLRs and other environmental sensors. We set out to provide a comprehensive analysis defining differences in response to TLR ligation between human neonates and adults. In response to most TLR ligands, neonatal innate immune cells, including monocytes and conventional and plasmacytoid dendritic cells produced less IL-12p70 and IFN-α (and consequently induced less IFN-γ), moderately less TNF-α, but as much or even more IL-1β, IL-6, IL-23, and IL-10 than adult cells. At the single-cell level, neonatal innate cells generally were less capable of producing multiple cytokines simultaneously, i.e., were less polyfunctional. Overall, our data suggest a robust if not enhanced capacity of the neonate vs the adult white-blood cell TLR-mediated response to support Th17- and Th2-type immunity, which promotes defense against extracellular pathogens, but a reduced capacity to support Th1-type responses, which promote defense against intracellular pathogens.